Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation

Nephrology Dialysis Transplantation

Volumn 25, Issue 6, 2010, Pages 2020-2023

  Petrakis, Ioannis ^a   Stylianou, Kostas ^a   Mavroeidi, Vasiliki ^a   Vardaki, Eleftheria ^a   Stratigis, Spyridon ^a   Stratakis, Stavros ^a   Xylouri, Irene ^a   Perakis, Constantinos ^a   Petraki, Constantina ^b   Nakopoulou, Lydia ^c   Daphnis, Eugene ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Autologous stem cell transplantation; Light chain deposition disease; Renal biopsy

Indexed keywords

CREATININE; ENALAPRIL; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; VALSARTAN;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG MEGADOSE; FATIGUE; FEMALE; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; LEG EDEMA; LIGHT CHAIN DEPOSITION DISEASE; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEINURIA; SYMPTOM; TACHYCARDIA; TREATMENT OUTCOME;

BIOPSY; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY; KIDNEY DISEASES; MIDDLE AGED; PARAPROTEINEMIAS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 77953006981     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq023     Document Type: Article

References (21)

1. Weichman K, Dember LM, Prokaeva T et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melpha-lan and autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 339-343
2. Randall RE, Williamson WCJ, Mullinax F et al. Manifestations of systemic light chain deposition. Am J Med 1976; 60: 293-299
3. Preud'homme JL, Aucouturier P, Touchard G et al. Monoclonal im-munoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994; 46: 965-972
4. Ronco P, Plaisier E, Mougenot B et al. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to path-ophysiology-driven therapy. Clin J Am Soc Nephrol 2006; 1: 1342-1350
5. Pozzi C, Amico MD, Fogazzi GB et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42: 1154-1163
6. Lin J, Markowitz GS, Valeri AM et al. Renal monoclonal immuno-globulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482-1492
7. Firkin F, Hill PA, Dwyer K et al. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis 2004; 44: 551-555
8. Lorenz EC, Gertz MA, Fervenza FC et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008; 23: 2052-2057
9. Mariette X, Clauvel JP, Brouet JC. Intensive therapy in AL amyloid-osis and light-chain deposition disease. Ann Intern Med 1995; 123: 553 letter
10. Komatsuda A, Wakui H, Ohtani H et al. Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am J Kidney Dis 2000; 35: E9
11. Hotta O, Taguma Y. Resolution of nodular glomerular lesions in a patient with light-chain nephropathy. Nephron 2002; 91: 504-505
12. Leung N, Dispenzieri A, Lacy MQ et al. Severity of baseline protein-uria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2007; 2: 440-444
13. Royer B, Arnulf B, Martinez F et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642-648
14. Teng J, Russell WJ, Gu X et al. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004; 84: 440-451
15. Zhu L, Herrera GA, Murphy-Ullrich JE et al. Pathogenesis of glo-merulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. Am J Pathol 1995; 147: 375-385
16. Russell WJ, Cardelli J, Harris E et al. Monoclonal light chain-mesan-gial cell interactions: early signaling events and subsequent pathologic effects. Lab Invest 2001; 81: 689-703
17. Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodelling in light-chain related glomerular damage. Kidney Int 2005; 68: 1590-1603
18. Keeling J, Teng J, Herrera GA. AL-amyloidosis and light chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 2004; 84: 1322-1338
19. Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol 2002; 22: 319-330
20. Kastritis E, Migkou M, Gavriatopoulou M et al. Treatment of light chain deposition disease with bortezomib and dexamethasone. Hae-matologica 2009; 94: 300-302letter
21. Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int 2008; 73: 1216-1219